During the past 8 years, The National Institutes of Health, including the National Heart, Lung, and Blood Institute (NHLBI) and NCCAM, sponsored the Trial to Assess Chelation Therapy (TACT). This study was the first large-scale, multicenter study designed to determine the safety and efficacy of EDTA chelation therapy for individuals with coronary heart disease.
Chelation means “grab” or “to bind”. Chelation therapy involves the regular infusion into the bloodstream of a synthetic solution-EDTA (ethylene diamine tetra-acetic acid) using an intravenous line to bind to heavy metals in the bloodstream and remove them.
Dr. Roy Heilbron is one of the most prominent cardiologists in the South Florida area who have been using standard methods in cardiology combined with chelation therapy to reduce coronary heart disease.
According to recent study reported during the American Heart Association annual meeting in Los Angeles, CA found that in 1,708 patients followed for an average of 4 years, those receiving chelation therapy had significantly fewer composite events compared with placebo — 26% versus 30% (HR 0.82, 95% CI 0.69 to 0.99, P=0.035).
Lamas, Goertz, Boineau, Mark, Rozema, Nahin, Drisko, and Lee (2012) argued that when the EDTA chelation is sometimes used for the treatment of coronary and peripheral artery disease, results have shown a potential to decalcify atherosclerotic plaque in patients with post-myocardial infaction.
Dr. Heilbron uses a cocktail of vitamin C, B vitamins, electrolytes, and the blood thinner heparin to “grab” heavy metals and minerals such as lead, mercury, copper, iron, arsenic, aluminum, and calcium and remove them from the body.
Lamas, G.A., Goertz, C., Boineau, R., Mark, D. B., Rozema, T., Nahin, R. L., Drisko, J. A., and Lee, K. L. (2012, November). Design of the trial to assess chelation therapy (TACT), American Heart Journal 163,7-12. doi:10.1016/j.ahj.2011.10.002